Browse Articles

Filter By:

  • Patient progression and response to immunotherapy are directly influenced by the presence and quality of tumour-infiltrating leukocytes (TILs). In a recent Cell publication, Wang, Zeng et al. demonstrate the functional role of circadian rhythms in altering TIL functionality and quantity, highlighting the therapeutic potential of leveraging this understanding. 

    • Gabrielle Brewer
    Research Highlight
  • This month, Nature Reviews Cancer launches Roadmap articles, in which we ask authors to provide a sense of direction to a field to encourage new lines of thinking and experimentation, as well as opportunities for collaboration.

    Editorial
  • In this Roadmap, Boire et al. consider the immediate causes of mortality in patients with cancer, a topic not often considered in either preclinical or clinical research, and provide recommendations for how we can stimulate research to advance our mechanistic understanding of these causes with a long-term view to improving the quality of life for patients with late-stage cancer.

    • Adrienne Boire
    • Katy Burke
    • Erik Sahai
    Roadmap
  • Although there has been increasing interest in developing models that mimic the tumour microenvironment (TME), these models often fail to replicate the complex 3D fibre architectures observed in tumours. Here, Ashworth and Cox address this, discuss the current design and fabrication challenges, and outline state-of-the-art biomaterial technologies useful for recreating tissue-specific 3D architectures in vitro.

    • J. C. Ashworth
    • T. R. Cox
    Review Article
  • The tumour immune microenvironment greatly affects responses to immune checkpoint therapies. In this Perspective, Zemek et al. explore the dynamic changes in response to both immunotherapy and conventional treatment and advocate for strategic combination therapies over time to enhance antitumour immune responses.

    • Rachael M. Zemek
    • Valsamo Anagnostou
    • Willem Joost Lesterhuis
    Perspective
  • Metastasis to the leptomeninges causes substantial neurological morbidity and mortality. Owing to the lack of mechanistic studies in this area, patients still face a bleak clinical prognosis. In this Review, Remsik and Boire provide a biology-focused overview of recent developments enabled by preclinical models and omics analyses and outline the need for further mechanistic research on leptomeningeal metastasis.

    • Jan Remsik
    • Adrienne Boire
    Review Article
  • In this Perspective, Holder et al. discuss the limitations of current predictive biomarkers of response to immune checkpoint inhibitors and the need to further explore static, dynamic and patient-specific biomarkers using novel tools, such as machine learning and consortia-level initiatives.

    • Ashley M. Holder
    • Aikaterini Dedeilia
    • Genevieve M. Boland
    Perspective
  • In this Tools of the Trade article, Erin Brown describes the development of CytoSPACE, a computational tool that aligns single-cell transcriptomes and spatial transcriptomic data, and highlights its use in identifying spatially resolved cell states in the tumour microenvironment.

    • Erin L. Brown
    Tools of the Trade
  • To establish microbiome-based screening for colorectal cancer, a study published in Nature Medicine tackled two key challenges: utilizing quantitative microbiome profiling and identifying covariates that might obscure the microbiota–colorectal cancer interactions.

    • Daniela Senft
    Research Highlight
  • Monteran et al. identified key interactions between granulocytes and T cells that promote an immunosuppressive bone microenvironment, enabling breast cancer metastasis.

    • Gabrielle Brewer
    Research Highlight
  • Parreno et al. provide evidence for epigenetically initiated cancers in Drosophila and show that cancer develops after transient loss of Polycomb group proteins in the absence of recurrent mutations.

    • Daniela Senft
    Research Highlight
  • In this Journal Club, Lim and Jeon discuss a recent study demonstrating the utility of noninvasive genomic profiling for subtyping Hodgkin lymphomas.

    • Sojung Lim
    • Yoon Kyung Jeon
    Journal Club
  • Kong et al. have now shown that Knudson’s two-hit hypothesis can be circumvented through the actions of the glycolytic metabolite methylglyoxal, which transiently inactivates the tumour-suppressive functions of BRCA2 leading to episodic mutagenesis and cancer genome evolution.

    • Anna Dart
    Research Highlight
  • In a ‘publish or perish’ culture, some scientists may resort to questionable research practices or even fraud. Scientific paper mills and artificial intelligence increasingly threaten the pursuit of truth in science. Structural changes, including heightened scrutiny of papers and authorship and better funding, are needed to ensure scientific integrity.

    • Elisabeth M. Bik
    World View
  • This Review provides an introductory guide to artificial intelligence (AI)-based tools for non-computational cancer researchers. Here, Perez-Lopez et al. outline the general principles of AI for image analysis, natural language processing and drug discovery, as well as how researchers can get started with each of them.

    • Raquel Perez-Lopez
    • Narmin Ghaffari Laleh
    • Jakob Nikolas Kather
    Review Article
  • In this Review, Paul et al. provide an overview of therapeutic antibodies as an important modality in cancer therapy today. They summarize the different approaches used by antibodies to target cancer cells including those of immune checkpoint inhibitors, bispecific antibodies and antibody–drug conjugates, as well as describing current strategies aimed at improving their efficacy and reducing toxicities.

    • Suman Paul
    • Maximilian F. Konig
    • Shibin Zhou
    Review Article
  • Two studies published concurrently in Nature report the development and preclinical activity of RMC-7977, a multi-selective inhibitor targeting the active, GTP-bound form of RAS.

    • Daniela Senft
    Research Highlight
  • The annual American Association for Cancer Research (AACR) meeting provides a platform for scientists, clinicians and other stakeholders to share the latest advances in cancer science and medicine. Here, we outline some highlights of the 2024 meeting.

    • Gabrielle Brewer
    Research Highlight
  • In this Tools of the Trade article, Victor Tieu describes the development of MEGA, a platform that exploits the RNA-targeting capability of CRISPR–Cas13d and demonstrates its use to improve the anti-tumour activity of CAR T cells.

    • Victor Tieu
    Tools of the Trade